135 related articles for article (PubMed ID: 36593625)
1. Somatic gene mutations in malignant steroid cell tumours and response to multiple treatments.
Nakanishi K; Fukagawa T; Yamada T; Suzuki S
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593625
[TBL] [Abstract][Full Text] [Related]
2. Malignant Sex Cord-Stromal Tumor, Not Otherwise Specified, Harboring FOXL2, p53, and TERT Promoter Mutations: Report of a Case.
Mayer R; Dandulakis M; Richards S; Roque DM; Staats PN
Int J Gynecol Pathol; 2020 Nov; 39(6):567-572. PubMed ID: 31789679
[TBL] [Abstract][Full Text] [Related]
3. [Ovarian malignant tumours. Efficacy of germ cell and sex cord tumour treatment protocol in Poland].
Popadiuk S; Korzon M; Chybicka A; Szmyd K; Dzierzega M; Trelińska J; Kowalczyk JR; Wiśniewska-Slusarz H; Woźniak W; Bilska K; Wachowiak J; Konatkowska B; Wysocki M; Krawczuk-Rybak M; Czauderna P; Szumera M; Sznurkowska K; Renke J
Med Wieku Rozwoj; 2006; 10(3 Pt 1):803-10. PubMed ID: 17317911
[TBL] [Abstract][Full Text] [Related]
4. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
5. Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
Marchetti C; Rosati A; Scaletta G; Pietragalla A; Arcieri M; Ergasti R; Palluzzi E; Scambia G; Fagotti A
Gynecol Oncol; 2019 Dec; 155(3):400-405. PubMed ID: 31606285
[TBL] [Abstract][Full Text] [Related]
6. [Testicular malignant tumours. Efficacy of germ cell and sex cord tumours treatment protocol in Poland].
Popadiuk S; Korzon M; Chybicka A; Szmyd K; Dzierzega M; Trelińska J; Kowalczyk JR; Wiśniewska-Slusarz H; Woźniak W; Bilska K; Wachowiak J; Konatkowska B; Wysocki M; Krawczuk-Rybak M; Czauderna P; Szumera M; Sznurkowska K; Renke J
Med Wieku Rozwoj; 2006; 10(3 Pt 1):811-7. PubMed ID: 17317912
[TBL] [Abstract][Full Text] [Related]
7. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
[TBL] [Abstract][Full Text] [Related]
8. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study.
Homesley HD; Bundy BN; Hurteau JA; Roth LM
Gynecol Oncol; 1999 Feb; 72(2):131-7. PubMed ID: 10021290
[TBL] [Abstract][Full Text] [Related]
9. Impact of taxane plus bevacizumab for ovarian sex cord tumor with annular tubules.
Sho T; Yanazume S; Fukuda M; Togami S; Kamio M; Kobayashi H
J Obstet Gynaecol Res; 2019 Jul; 45(7):1423-1428. PubMed ID: 31060113
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
12. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
[TBL] [Abstract][Full Text] [Related]
13. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
[TBL] [Abstract][Full Text] [Related]
14. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.
Gershenson DM; Morris M; Burke TW; Levenback C; Matthews CM; Wharton JT
Obstet Gynecol; 1996 Apr; 87(4):527-31. PubMed ID: 8602303
[TBL] [Abstract][Full Text] [Related]
15. Management of early ovarian cancer: germ cell and sex cord-stromal tumors.
Gershenson DM
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S62-72. PubMed ID: 7530680
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics and genetic variations of uterine tumours resembling ovarian sex cord tumours.
Ye S; Wu J; Yao L; He J
J Clin Pathol; 2022 Nov; 75(11):776-781. PubMed ID: 34348985
[TBL] [Abstract][Full Text] [Related]
17. Successful multimodality therapy of recurrent multifocal juvenile granulosa cell tumor of the ovary.
Erdreich-Epstein A; Monforte HL; Lavey RS; Joshi S; Phillips JD; Villablanca JG
J Pediatr Hematol Oncol; 2002; 24(3):229-33. PubMed ID: 11990313
[TBL] [Abstract][Full Text] [Related]
18. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
19. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
20. Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.
Ray-Coquard I; Harter P; Lorusso D; Dalban C; Vergote I; Fujiwara K; Gladieff L; Lück HJ; Floquet A; Chevalier-Place A; Schnelzer A; Pignata S; Selle F; Sehouli J; Brocard F; Mangili G; Pautier P; De Giorgi U; Provansal M; Heudel PE
JAMA Oncol; 2020 Dec; 6(12):1923-1930. PubMed ID: 33030515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
